7:00 PM
 | 
Feb 07, 2013
 |  BC Extra  |  Politics & Policy

FDA: AD biomarkers won't yet support approval

FDA said the use of a biomarker as either a single primary endpoint or secondary endpoint measure will not yet support approval of a product to treat early Alzheimer's disease (AD). According to

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >